Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

(2020) David S Hong et al.   LANCET ONCOLOGY

Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.

(2020) Christian Diego Rolfo et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

(2019) Jordi Rodon et al.   NATURE MEDICINE

TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

(2019) Ezra Y Rosen et al.   CLINICAL CANCER RESEARCH

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

(2018) Sarah Watson et al.   BRITISH JOURNAL OF CANCER

Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)

(2017) Riccardo Soffietti et al.   NEURO-ONCOLOGY

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial

(2016) L. Belin et al.   ANNALS OF ONCOLOGY

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

(2016) Milan Radovich et al.   Oncotarget

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment

(2013) Christophe Le Tourneau et al.   JOURNAL OF CLINICAL ONCOLOGY

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

(2012) N. Penel et al.   ANNALS OF ONCOLOGY

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

(2012) C Le Tourneau et al.   BRITISH JOURNAL OF CANCER

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY